Versant Ventures

www.versantventures.com

VCMatch tracks Versant Ventures as an investor focused on Biotech, Medtech, and Pharma companies, Pre-Seed and Seed rounds, and United States, Switzerland, and Europe markets. Upload your deck to compare your startup against the full private matching profile.

Check Size

Not specified

Stages

Pre-Seed, Seed, Series A

Focus Areas

Biotech, Medtech, Pharma

Geography

United States, Switzerland, and Europe

Investment Thesis

Versant operates as an active company creator and early-stage biotech investor that pairs in-house scientific discovery capabilities with academic founders to translate laboratory science into new companies. Their model emphasizes hands-on, operational involvement—providing discovery infrastructure, multi-disciplinary scientific teams, and experienced investing and operating leaders to launch and scale novel therapeutics and medical-device ventures.

Is Versant Ventures right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

Versant Ventures is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Medtech, Pharma, and Digital Health, especially across United States, Switzerland, and Europe.

Focus statement

Versant focuses on launching and financing novel biotechnology companies (early-stage therapeutics and device/diagnostic platforms) by combining in-house discovery engines with academic founders; portfolio examples show specific activity in ophthalmology (drug delivery, sustained non‑invasive therapies) and surgical precision devices.

Value Add

Operates proprietary Discovery Engines: "Versant’s Discovery Engines comprise in-house teams of multi-disciplinary scientists working in state-of-the-art laboratory facilities to enable the launch of novel biotechnology companies with academic founders."
Hands-on company creation rather than passive financing—team bios stress roles in new company creation, launching/investing in portfolio companies, and operational leadership (e.g., heads of Ridgeline Discovery Engine).
Deep scientific and drug-discovery expertise on the investment team (multiple Ph.D. and MD operating partners with prior pharma R&D and BD leadership), enabling technical due diligence and program leadership.
Track record across therapeutics and medical devices with concrete portfolio examples (ForSight VISION4/5 focused on ocular drug delivery and non-invasive sustained therapies; WaveTech commercializing intra-operative measurement system).